Biogen hauls in $6B amid biopharma's M&A fever pitch

Days after Gilead Sciences ($GILD) spurred a wave of buyout rumors with its effort to bring in $10 billion, Biogen ($BIIB) laid out plans to raise $6 billion of its own, providing few details as it looks to bolster its cash position. The Cambridge, MA, drugmaker priced four series of senior notes, maturing between 2020 and 2045, in an offering expected to close next week. Some of the money will go toward a previously announced share repurchase program, the company said, with the rest tabbed for the vague "working capital and other general corporate purposes." More

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera